| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| DeLong Mark Jeffrey | Chief Business & Strat Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM | /s/ David Watson, attorney-in-fact for Mark DeLong | 23 Jan 2026 | 0001856078 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLS | Common Stock | Sale | $73,371 | -3,371 | -4.1% | $21.77 | 78,353 | 22 Jan 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026. |